Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 6, Pages 1490-1496Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1872070
Keywords
COVID-19; hyperimmune plasma; immunodeficiency; onco-hematological patients
Categories
Ask authors/readers for more resources
This study described the use of hyperimmune plasma therapy in immunocompromised patients with hematological disorders during the SARS-CoV-2 outbreak, showing positive outcomes such as clinical improvement, recovery, and viral clearance. While further research is needed, the results suggest a specific role for hyperimmune plasma therapy in hematological patients.
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, patients with defective immunity after chemo-immunotherapy due to hematological disorders showed prolonged symptoms and worse prognosis of coronavirus disease-2019 (COVID-19) pneumonia, probably due to inadequate adaptive immune response and noneffective viral clearance. We describe a single-center series of hematological immunocompromised patients undergoing passive immunization with hyperimmune plasma for persistent COVID-19 symptoms. In all cases, such treatment was well tolerated and contributed to clinical and radiological improvement and recovery; viral clearance was also achieved in a patients' subset. Although requiring further investigation, these results suggest a specific role for hyperimmune plasma administration in hematological patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available